At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,530 enrolled
Drug / intervention
vibegron +3 moredrug
Likely dose
vibegron 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
In Brief
A Phase 3 clinical trial evaluating vibegron, Vibegron placebo, and 2 other interventions for Overactive Bladder. Completed, enrolled 1,530 participants across 215 sites in 6 countries.
Detailed Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesCanada, Hungary, Latvia, Lithuania, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionJan 2019
Study CompletionFeb 2019
TodayJul 2026
First PostedApr 10, 2018
Enrollment StartMar 26, 2018
Primary CompletionJan 10, 2019
Study CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.2 years ago
Interventions
vibegrondrug
single daily oral dose of vibegron 75 mg for 12 weeks
Vibegron placebodrug
placebo to match vibegron (experimental drug)
Tolterodine Tartrate ERdrug
single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
Tolterodine placebodrug
placebo to match tolterodine (active comparator)